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Objective: Abdominal aortic aneurysm (AAA) development is associated with increased angiogenesis and overexpression
of vascular endothelial growth factor (VEGF). Inhibition of angiogenesis results in attenuation of experimental
aneurysms. This study investigated the effects of recombinant human (rh)VEGF on experimental aneurysms.
Methods: Apolipoprotein E-deficient (apoE–/–) mice were assigned to one of four groups: (1) normal saline infusion
(sham), (2) angiotensin-II (AngII) infusion, (3) AngII infusion plus 100 g daily rhVEGF for 14 days
(AngII14dVEGF), or (4) AngII infusion plus 100g daily rhVEGF for 21 days (AngII21dVEGF). Aortic maximum
diameter and cross-sectional area were determined by magnetic resonance imaging and microscopy. All mice were
sacrificed at day 28.
Results: Aneurysms developed in all mice in the AngII14dVEGF and AngII21dVEGF groups by day 21 compared
with 40% in the AngII group. Treatment with rhVEGF increased maximum aortic diameter (P < .002) and cross-
sectional area of aneurysms (P< .005) at day 21. This effect was maintained at day 28 (P < .0005). Decreasing rhVEGF
treatment from 21 to 14 days did not attenuate aneurysm formation. Treatment with rhVEGF upregulated matrix
metalloproteinase 2 gene expression within the aortic wall (P < .0009).
Conclusions: Treatment with rhVEGF intensified the formation of AngII-induced aneurysms. Further studies are needed
to investigate if antiangiogenic therapy may be a valid medical therapy against aneurysm expansion or rupture. ( J Vasc
Surg 2010;52:159-66.)
Clinical Relevance: Abdominal aortic aneurysm (AAA) rupture ranks as the 13th leading cause of death in the United
States and is responsible for 0.8% of all deaths. No pharmacologic treatment is currently available to inhibit aneurysm
expansion or rupture, and the only treatment option is surgical repair by conventional or endovascular means. Previous
studies have demonstrated that the AAA rupture site is associated with increased angiogenic response, including increased
expression of vascular endothelial growth factor. This study demonstrated that recombinant human vascular endothelial
growth factor promoted the severity of experimental aneurysm formation. Angiogenesis may be a valid target for
therapeutic intervention against aneurysms.Abdominal aortic aneurysm (AAA) rupture is the 13th
most common cause of death in the Western world,1 and
the only effective approach to preventing aneurysm rupture
remains surgical repair by conventional or endovascular
means. Although collective endeavors in basic science re-
search during the past 2 decades have led to progress in the
understanding of aneurysm development and expansion,
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The association between angiogenesis and human an-
eurysms has been recognized by previous investigators2-4
who suggested that angiogenesis might contribute toward
the development of aneurysms. The localization of in-
creased angiogenesis and increased expression of proangio-
genic cytokines to the site of aneurysm rupture in humans5
implied a further role for angiogenesis in end-stage aneu-
rysm disease and aneurysm rupture.
Extracellular proteolysis is an absolute requisite for
angiogenesis, primarily contributing toward proteolytic
degradation of the vascular basement membrane and re-
modeling of the extracellular matrix to allow endothelial
cells to migrate and invade into the surrounding tissue.6 It
is this link between proangiogenic cytokines and induction
of extracellular proteolysis that makes these cytokines po-
tentially relevant in aneurysm disease. Recently, Tedesco et
al7 demonstrated that the mural expression of vascular
endothelial growth factor (VEGF) receptor (VEGFR), as
determined by fluorescent imaging and VEGFR-2 immu-
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in experimental aneurysms. These authors also showed that
inhibition of angiogenesis resulted in the attenuation of
experimental aneurysms.
To date, the effects of proangiogenic mediators in
experimental models of aneurysm have never been tested,
and whether the observed overexpression of proangiogenic
cytokines at the site of aneurysm rupture is a cause or effect
of end-stage aneurysmal disease remains unknown. The
present study investigated the effects of recombinant hu-
man (rh) VEGF on angiotensin (Ang)-II–induced aneu-
rysm in apolipoprotein (Apo) E–/– mice. The results indi-
cated that rhVEGF significantly enhanced AAA formation
and upregulated gene expression of matrix metalloprotein-
ase (MMP)-2 in the aortic wall.
METHODS
Experimental animals. TheHomeOffice Science and
Research Group (Animals Scientific Procedures Division)
approved all animal protocols. Six-month-old apoE–/–
male mice (Jackson Laboratories, Bar Harbor, Me) under-
went a minimum 1-month acclimatization period. Water
and regular mouse chow was available 24 hours daily. Mice
were assigned to one of four groups: (1) infusion of normal
saline (sham), (2) infusion of AngII (1000 ng/kg/min,
Sigma-Aldrich Corp, St. Louis, Mo), (3) infusion of AngII
plus 14 days daily intraperitoneal (IP) injections of 100 g
rhVEGF (AngII14dVEGF, short-duration group), or (4)
infusion of AngII plus 21 days daily IP injections of 100 g
rhVEGF (AngII21dVEGF, long-duration group; Fig 1).
The short-duration group commenced daily rhVEGF
injections (Genentech Inc, South San Francisco, Calif)
from day 15, and the long-duration group commenced
daily rhVEGF injections from day 8. Mice from the sham
group and AngII-only group received daily IP saline injec-
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injection Day 8
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Day 15
Daily IP 100µg VEGF injection 
Day 8
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Fig 1. Schematic diagram of study design.AngII,Angiotensin II;
IP, intraperitoneal; VEGF, vascular endothelial growth factor.tions from day 8. All mice were sacrificed on day 28.Implantation of miniosmotic pumps. Alzet model
2004 mini-osmotic pumps (Durect Corp, Cupertino,
Calif) were loaded with individual concentrations of AngII
(variable according to individual animal weight) for 28 days
of continuous delivery of 1000 ng/kg/min of AngII.
These were incubated in normal saline at 37°C for 24 hours
before subcutaneous implantation at the interscapular area.
The miniosmotic pumps implanted in the sham group were
loaded with normal saline.
Magnetic resonance imaging protocol. Mice under-
went magnetic resonance imaging (MRI) on days 21 and
28 (before sacrifice). MRI data were obtained using a
Varian Unity INOVA imaging system fitted with a 4.7-T
horizontal bore magnet. Coronal scout images were ac-
quired to allow reproducible positioning of axial images
aligned with the central slice at the superior end of the left
kidney (Fig 2). In each mouse, nine axial T1-weighted spin-
echo cross-sectional images were acquired with 2-mm-thick
contiguous slices. Using the Varian ImageBrowser (Varian
Medical Systems, Palo Alto, Calif) software and delineation
of regions of interest, an operator (F. H.) who was blinded
to the experimental arm of the mice determined the ab-
dominal aorta diameter (mm) and cross-sectional area
(mm2) in each cross-section were determined. Details of
the experimental protocol are presented in the Supplement
Fig 2. Left, Representative magnetic resonance image coronal
section with (Right) photograph of corresponding arterial tree
showing suprarenal abdominal aortic aneurysm. In each mouse,
nine axial T1-weighted spin-echo cross-sectional images (green
lines) were acquired with 2-mm-thick contiguous slices. To ensure
reproducible positioning of axial images, the central slice (5th) was
aligned at the superior pole of the left kidney.(online only).
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day treatment period, mice were sacrificed and blood was
drawn from the right ventricle. Tomaximize RNA stability,
aortas were perfused with RNALater (Applied Biosystems,
Warrington UK) through the heart, and the entire arterial
trees were rinsed with RNALater while in situ. A dissection
microscope (Olympus, Tokyo, Japan) was used to carefully
dissect the arterial tree from fat and connective tissue and
was photographed. Ex vivomeasurements of diameter were
taken with calibrated calipers through the entire length of
the aorta to determine the region of maximum dilatation.
Samples for molecular analysis were harvested from aneu-
rysmal segments of the aorta and placed in RNALater at
–20°C until extraction of total RNA. As previously de-
scribed,5 total RNA was extracted using RNeasy Fibrous
Tissue RNA extraction kit (Qiagen, West Sussex, UK) and
checked for integrity and concentration using RNA 6000
Nano LabChip Kit and Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, Calif).
Quantitative real-time reverse-transcription poly-
merase chain reaction. Complimentary DNA (cDNA)
was synthesized from total RNA by reverse-transcription
using a high-capacity cDNA archive kit (Applied Biosys-
tems). Qualitative reverse-transcription polymerase chain
reaction (QRT-PCR) was done with the Mx4000 Multi-
plex Quantitative PCR System (Stratagene, Edinburgh,
UK) using TaqMan Gene Expression Assays (Assays-on-
Demand Gene Expression Products, Applied Biosystems,
UK) and TaqMan Universal PCR Master Mix.
Transcript levels were normalized to 18s rRNA (inter-
nal control). The expression of genes encoding for the
proinflammatory cytokines E-selectin and tumor necrosis
factor (TNF), the proteolytic enzymes from the MMP
family (membrane type-1-MMP [MT1-MMP] and MMPs
2 and 9) and the plasmin activator system (urokinase
plasminogen activator [uPA] and tissue plasminogen acti-
vator [tPA]) was determined. Details of the experimental
Table I. Weight and mortality dataa
Variableb Saline An
Total number 5 1
Weight, g
Pretreatment 32.5  0.8 34.0
4th week 35.3  0.9 37.1
Survived to 28 days 4 (80) 5 (
Spontaneous death
Rupture 0 2 (
Nonrupture 1 2 (
Schedule 1 sacrifice
Paraplegia 0 2 (
General lethargy 0
Total aneurysmsd 0 (0) 9 (
AngII, Angiotensin II; VEGF, vascular endothelial growth factor.
aP values for all variables were not significant.
bData are presented as mean  standard error of the mean, or No. (%).
cOne mouse in each of these groups did not develop an aneurysm.
dIncludes mice that died 28 days.protocol are presented in the Supplement (online only).Statistics. All data were reported as mean  standard
error of the mean. Multiple comparisons of mean values of
aortic aneurysm diameters, cross-sectional areas, and gene
expression were performed by one-way analysis of variance,
followed by a subsequent Newman-Keuls multiple compar-
ison test. Differences were considered statistically signifi-
cant at a value of P  .05.
RESULTS
Weight and mortality data. No significant differ-
ences were observed for weight at the beginning and com-
pletion of the study among all experimental groups of mice
(Table I).
Necropsy was performed 24 hours on animals that
died before completion of study. These animals were not
included in AAA quantification analysis but only in the
mortality data.
The mortality rate was increased in the groups that
received AngII infusions compared with the sham group,
although this did not reach statistical significance (Table I).
Aortic ruptures causing death occurred in AngII (n  2),
AngII14dVEGF (n 2), and AngII21dVEGF (n 1)
groups. All aortic ruptures occurred between days 6 and 14.
Paraplegia or general lethargy necessitated schedule 1 eu-
thanasia before 28 days of infusion had been completed in
AngII (n  2), AngII14dVEGF (n  3), and AngII
21dVEGF (n 3; P .48). In the placebo control group,
one mouse died on day 18 after insertion of the osmotic
pump, and necropsy revealed normal aorta.
Including mice that died before 28 days, the incidence
of aneurysms was 0% (saline), 81% (AngII), 89% (AngII
14dVEGF), and 90% (AngII21dVEGF). The aneurysms
in mice that died 28 days were excluded from further
analysis because their size would have been different had
they been allowed to develop to 28 days.
Effect of rhVEGF onmaximum diameter and cross-
sectional areas. Treatment with rhVEGF increased the
AngII14dVEGF AngII21dVEGF
9 10
9 34.8  1.1 35.0  0.7
0 36.0  1.5 35.5  1.2
3 (33) 4 (40)
2 (22) 1 (10)
1 (11) 2 (20)
2 (22)c 2 (20)c
1 (11) 1 (10)
8 (89) 9 (90)gII
1
 0.
 1.
45)
18)
18)c
18)c
0
81)maximum diameter and maximum cross-sectional area of
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Fig 3. Angiotensin (Ang) II-induced abdominal aortic aneurysm (AAA) size was significantly increased at days 21 and 28 in
apolipoprotein E–/– mice treated with vascular endothelial growth factor (VEGF) for 14 (AngII14dVEGF) or 21
(AngII14dVEGF) days.A,Representativemacroscopic photographs of the AAA are shownwith corresponding cross-sectional
magnetic resonance imaging scans at day28.Themaximumdiameterof the aorta is outlinedby the red line. Box andwhisker plots
show theAAAmaximumdiameter at (B)day 21 and (C)day 28 andmaximumcross-sectional area at (D)day 21 and (E)day 28
in saline-infused (n 4), AngII-infused (n 5), Ang II14dVEGF-infused (n 3), and AngII21dVEGF-infused (n 4)
mice. #P .05 vs AngII infusion; §P .05 vs Ang II infusion; †P .05 vs AngII infusion; ††P .05 vs Ang II infusion; ‡P .01
vs AngII infusion; ‡‡P .05 vs Ang II infusion; *P .05 vs Ang II infusion; **P .05 vs Ang II-infusion. The horizontal line in
the middle of each box indicates the median; the top and bottom borders of the box mark the 75th and 25th percentiles,
respectively, and the whiskers mark the 90th and 10th percentiles.
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day 21 demonstrated a 52% increase in maximum aortic
diameter (P  .05) and a 100% increase in maximum
cross-sectional area (P  .05) in the short-duration group
(AngII14dVEGF) compared with AngII mice. Similarly,
a 38% increase in maximum aortic diameter (P  .05) and
a 68% increase in the maximum cross-sectional area (P 
.05) occurred in the long-duration group (AngII
21dVEGF). The difference in the maximum aortic diameter
or cross-sectional area between short-duration and long-
duration VEGF groups was not statistically significant.
MRI measurements at day 28 demonstrated a 36%
increase in maximum aortic diameter (P  .05) and a 76%
increase in maximum cross-sectional area (P  .05) in the
short-duration group (AngII14dVEGF) compared with
AngII mice. A 25% increase in maximum aortic diameter
(P  .05) and a 52% increase in maximum cross-sectional
area (P .05)occurred in the long-durationgroup(AngII
21dVEGF). At day 28, no statistically significant difference
was evident in maximum diameter or maximum cross-
sectional area between short- and long-duration VEGF
groups.
After mice were sacrificed at day 28, ex vivo measure-
ments demonstrated that maximum aortic diameter was
increased by 67% (P  .01) in the short-duration group
(AngII14dVEGF) and by 51% (P  .01) in the long-
duration group (AngII21dVEGF) compared with AngII
mice. A comparison of ex vivo aortic maximum diameter mea-
surements with in vivo measurements byMRI at day 28 (Fig 4,
online only) demonstrated that these two measurements were
highly correlated with each other (Pearson r2 0.88).
Aneurysm formation in rhVEGF-treated mice.
Aneurysms formed earlier in rhVEGF-treated mice. Aortic
aneurysm was defined as 50% enlargement of maximum
abdominal aortic diameter, in line with current clinical
definitions.8 The average diameter of the suprarenal aorta
in sham mice at 3 weeks was 1.23 mm and a threshold of
1.85 mm was therefore set as the minimum diameter for
incidence of aneurysm formation. Aneurysms had already
developed at day 21 in all mice in the AngII14dVEGF
and AngII21dVEGF groups compared with only two
Table II. Summary of gene expressions (arbitrary units no
Saline An
Gene Mean  SEM Mean 
MMP-2 2.20  0.26 1.76 
MMP-9 4.96  0.16 5.09 
MT1-MMP 6.42  0.15 6.79 
uPA 6.00  0.31 5.55 
tPA 5.65  0.16 5.40 
E-selectin 5.20  0.25 4.75 
TNF 4.71  0.32 4.19 
AngII, Angiotensin II;MMP,matrix metalloproteinase;MT1-MMP,memb
tPA, tissue-type plasminogen activator; uPA, urokinase-type plasminogen a
aComparison used one-way analysis of variance.
bSignificant.(40%) of the AngII mice.At day 28, the average diameter of the suprarenal aorta
in the control mice was very similar (1.25 mm), and a
threshold of 1.88 mm was therefore set as the minimum
diameter for incidence of aneurysm formation. At this time
point, aneurysm formation was evident in 80% of AngII
mice. From days 21 to 28, there was an increase in maxi-
mum aortic diameter (14%) and maximum cross-sectional
area (25%; P  .05) in mice from the AngII group. In the
rhVEGF-treated groups, no statistically significant changes
to diameter or cross-sectional area were evident between
days 21 and 28. These data suggested that aneurysms
formed more quickly in mice exposed to a proangiogenic
stimulus.
Effect of VEGF on MMP-2 gene expression in the
aortic wall. Gene expression of MMP-2 was significantly
increased (P .0009) in aneurysmal sections of the aorta in
the pooled rhVEGF-treated group compared with aneurys-
mal sections of the aorta in the AngII group or normal aorta
in the saline group (Table II). There was no difference in
gene expression of MMP-9, MT1-MMP, uPA, tPA, E-
selectin, or TNF.
DISCUSSION
This study investigated the functional significance of
increasing the exposure to the proangiogenic VEGF in
experimental aneurysms. VEGF was selected for investiga-
tion because it is a potent inducer of angiogenesis and has
consistently been shown to be a potentially important
participant in aneurysm development3 and rupture.5 Previ-
ous work has shown VEGF is increased in aneurysmal
tissues.3 The present study demonstrated that exogenous
treatment with rhVEGF led to earlier development and
increased maximum expansion of AngII-induced aneu-
rysms. This enhancement of aneurysms after rhVEGF treat-
ment was independent of the duration of rhVEGF treat-
ment.
In addition to VEGF, an increase in other proangio-
genic molecules, such as v-integrin, VE-cadherin, mono-
cyte chemoattractant protein-1, and vimentin, has also
been observed at the site of AAA rupture in humans.5,9
lized to 18S recombinant RNA)
AngIIVEGF (pooled)
Mean  SEM P valuea
4.31  0.13 .0009b
5.14  0.36 .94
7.00  0.06 .40
6.03  0.09 .46
5.60  0.07 .52
5.04  0.07 .39
4.80  0.21 .36
pe-1-MMP; SEM, standard error of the mean; TNF, tumor necrosis factor;
r; VEGF, vascular endothelial growth factor.rma
gII
SEM
0.22
0.46
0.32
0.27
0.17
0.21
0.26
rane ty
ctivatoHowever, data from the present study demonstrated that
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aortic rupture within the 28-day experimental period.
MRI has previously been validated as a robust nonin-
vasive imaging technique for detecting in vivo phenotypic
abnormalities, including the characterization of atheroscle-
rotic plaque,10-14 diagnosis, and measurements of arterial
remodeling during aortic lumen enlargement in apoE–/–
mice.15,16 In the present study, MRI using a Varian Unity
INOVA imaging system fitted with a 4.7-T horizontal bore
magnet was used for in vivo monitoring, detecting, and
measuring maximum diameter and cross-sectional area of
AngII-induced aneurysms in apoE–/– mice. This work en-
dorsed the potential of MRI to obtain accurate vessel
dimensions in diseased abdominal aorta, verified against
macroscopic measurements, and to monitor disease pro-
gression by serial imaging at different time points.
No current studies have clearly demonstrated an effect
of age on the development of AngII-induced aneurysms.
The use of younger mice is limited by the practical con-
straints of their smaller size and therefore difficulties in
implantation of the Alzet miniosmotic pumps. Effective
drug delivery required the body weight of mice to be at
least 20 grams. We used 6-month-old mice in this study
according to the methods described in the first published
article on AngII-mediated aneurysms.17 Mice ranging in
age from 3 to 11 months at the initiation of AngII infusion
have been used, and the described incidence of AngII-
induced aneurysms has been fairly consistent, at 70% to
90%, in hyperlipidemicmice. The incidence of aneurysms in
the AngII group (without VEGF) was 80% at 28 days, and
this is consistent with that of other published studies.
On the other hand, the use of older mice might have
resulted in the lower-than-anticipated overall survival to 28
days. The rates of aortic rupture (all day 14) were 18%
(AngII), 22% (AngII14dVEGF), and 10% (AngII
21dVEGF). These results were consistent with rates of
10%18 to 40%19 published in previous reports. However,
the overall survival was low due to other causes such as
paraplegia and general lethargy that necessitated schedule I
sacrifice. Paraplegia is a recognized complication of AngII
infusion.20
Saraff et al18 demonstrated that neovascularization
within AngII-induced aneurysms was a late-stage response
that occurred during maturation of aneurysmal tissues be-
tween days 14 and 28. In this study, rhVEGF IP injection
was started at day 15 (short-duration group) to coincide
with this response to investigate the effects of proangio-
genic cytokine on the angiogenic process. IP rhVEGF
injection was also started at day 8 (long-duration group) to
investigate the effects of introducing a proangiogenic cyto-
kine before any “naturally occurring” neovascularization
process within the developing aneurysms.
The results indicated that the effects of rhVEGF were
not different, whether it was administered before (day 8) or
during (day 15) the neovascularization process. This sug-
gested that there was a dose-saturating effect, in which 14
days of rhVEGF treatment resulted in maximum enhance-
ment of the aneurysm, with no further increases demon-strable with an earlier additional 7 days of rhVEGF. It is
interesting to note that aneurysms in the short-duration
group were larger than aneurysms that had longer exposure
to rhVEGF, but this result did not reach statistical signifi-
cance.
Tedesco et al7 recently reported that mural VEGFR
expression was increased in AngII-induced aneurysms in a
diameter-dependent fashion. Because in vivo measure-
ments of VEGFR expression using near-infrared fluores-
cent imaging is not yet possible due to intrinsic autofluo-
rescence, there are currently no data on the temporal
relationship between VEGFR expression and the develop-
ment of aneurysms. The time course of VEGFR expression
may be a possible explanation for the larger (although not
statistically significant) size of aneurysms in the short-duration
VEGF group compared to the long-duration group.
The regulation of MMP and serine protease expression
by VEGF is well described. The regulation of MMPs and
tissue inhibitor of matrix metalloproteinases (TIMPs) in
endothelial cells by VEGF is variable and cell-type depen-
dent:6
● In human umbilical vein endothelial cells, VEGF in-
creased MMP-1, MMP-2, and TIMP-1, and this
change was accompanied by increased activation of
MMP-2.21,22
● In human dermal microvascular endothelial cells,
VEGF increased MMP-2, MMP-9, and MT-1 MMP,
had no effect on MMP-1, and decreased TIMP-1 and
TIMP-2.23,24
● Circulating VEGF induced MMP-9 expression in
bone marrow.25
● VEGF treatment enhanced production of MMPs-1,
-3, and -9 by human smooth muscle cells.26
● In bovine microvascular endothelial cells27 and human
umbilical vein endothelial cells,28 VEGF increased tPA
and uPA.
The messenger RNA (mRNA) levels of MMPs-2 and
MMPs-9, MT1-MMP, tPA, and uPA were analyzed in this
study to investigate if VEGF treatment had any effect on
the expression of these VEGF downstream target genes in
the aortic tissue of the mice. In addition, this study ana-
lyzed the gene expression of the proinflammatory cytokines
selectin-E and TNF. There is evidence that VEGF may act
as a proinflammatory cytokine by increasing E-selectin
mRNA in cultured endothelial cells.29 Furthermore, VEGF
“primed” endothelial cells, sensitizing them to TNF and
leading to heightened selective proinflammatory responses,
including upregulation of E-selectin.30
This study showed that rhVEGF treatment led to the
upregulation of gene expression of MMP-2 in aortic aneu-
rysm tissues. No differences in gene expression of MMP-9,
MT1-MMP, uPA, tPA, E-selectin, or TNF were demon-
strable in aortic tissues harvested at day 28 after treatment.
This suggested that proteolysis by MMP-2 may be one
mechanism of enhanced aneurysm formation in this group
of mice and that this was independent of an E-selectin-
induced or TNF-induced inflammatory response, or that
JOURNAL OF VASCULAR SURGERY
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time points.
This study had several limitations. First, the sample size
of mice that survived to 28 days was small. As such, the
results from this study should be cautiously viewed as
preliminary.
Second, this study investigated an accentuation of func-
tion rather than a loss of function. A loss of function
experiment might represent a more authoritative method
of proving a causal role for VEGF in aneurysm disease.
However, experiments using VEGF-knock-out mice are
not possible because targeted inactivation of VEGF genes
causes embryonic lethality in mice.31
Another limitation was that tissue VEGF concentra-
tions were not assayed due to technical difficulties and
therefore there was no definitive proof of VEGF infiltration
into aortic tissue. There are currently no studies that pro-
vide data on the kinetics of intraperitoneally administered
rhVEGF in apolipoprotein-deficient mice.
Asahara et al32 demonstrated that 10-g IP injections
of rhVEGF in mice daily for a week increased circulating
endothelial progenitor cells and augmented corneal neo-
vascularization. Celletti et al33 demonstrated that even
single IP injections of low-dose (2 g/kg) rhVEGF had
effects on augmenting neovascularization in the thoracic
aorta of hyperlipidemic mice. The results from these previ-
ous studies suggested the higher dose of daily IP rhVEGF
injections (100g) as used in the present study was likely to
have an effect of augmenting the neovascularization pro-
cess within the mice aortas.
Because all the available mouse aortic tissues were used
for molecular analysis with QRT-PCR, this study was not
able to analyze the histologic appearance of the aortic
tissues for the extent of angiogenesis in rhVEGF-treated
mice. Further studies are needed to clarify if rhVEGF admin-
istration was associated with increased CD32 cells or micro-
capillaries and monocyte/macrophage infiltration-2 (or simi-
lar). The area of aneurysmwall that responded to the rhVEGF
should also be investigated. The protein expression of
MMP-2 should also ideally be investigated.
CONCLUSIONS
This study showed that VEGF enhanced the formation
of AngII-induced aneurysms in apoE–/–mice and increased
gene expression ofMMP-2within the aortic aneurysmwall.
These findings suggest an important role for VEGF in the
process of experimental aneurysm development. Further
work is needed to determine if anti-VEGF treatment has
any effect in retarding aneurysm expansion or preventing
aneurysm rupture.
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Magnetic resonance imaging protocol. Mice under-
went magnetic resonance imaging (MRI) scans at day 21
and day 28 (before euthanasia). MRI data were obtained
using a Varian Unity INOVA imaging system fitted with a
4.7-T horizontal bore magnet. Mice were positioned su-
pine within a 63-mm-diameter quadrature imaging coil
into which heated air was blown to maintain normal body
temperature. Coronal scout images were acquired to allow
reproducible positioning of axial images aligned with the
central slice at the superior end of the left kidney (Fig 1).
Because of the ferromagnetic core of the infusion pump
spin echo (rather than gradient echo), images were ac-
quired with strong slice selection and readout gradients to
minimize image distortions. Nine axial T1-weighted spin-
echo cross-sectional images were acquired with 2-mm-
thick contiguous slices with repetition time of 400 millisec-
onds, echo time of 8.5milliseconds, and 16 averages. Outer
slice 12-mm-thick saturation bands were used to suppress
the high-intensity blood signal of the lumen. In-plane
image resolution was 512 	 256 over a 4-cm field of view
and zero-filled to 1024 	 1024 for region-of-interest
(ROI) analysis of abdominal aorta. Using the Varian Im-
ageBrowser software and delineation of the ROI, an oper-
ator (F.H.) whowas blinded to the experimental arm of the
mice determined abdominal aorta diameter (mm) and
cross-sectional area (mm2) in each cross-section.
Real-time quantitative reverse-transcription poly-
merase chain reaction. Qualitative reverse-transcription
polymerase chain reaction (QRT-PCR) mixtures were es-(Pearson r2  0.88).tablished according to manufacturer’s recommendations
(Assays-on-Demand Gene Expression Products and Taq-
ManUniversal PCRMaster Mix, Applied Biosystems, War-
rington, UK). Each sample was run in triplicates, and for all
reactions, negative controls were run with no template
present. In addition, total RNA from mice samples was
used for sham reverse-transcription reactions with no re-
verse transcriptase present and then subjected to standard
PCR using 18S ribosomal RNA (rRNA) primers to verify
that no amplification was produced.
QRT-PCR was done using an Mx4000 Multiplex
Quantitative PCR System (Stratagene, UK). Each PCR
cycle started with an initial 10-minute denaturation step at
95°C, followed by 40 cycles of shuttle heating at 95°C for
15 seconds, and at 60°C for 1 minute. The associated
Mx4000 software was used to analyze the data and deter-
mine the threshold count (Ct). The specimens were nor-
malized to the endogenous reference control 18S rRNA.
For each sample, Ct
target gene and Ct
18S rRNA were deter-
mined, and 
Ct  Ct
target gene  Ct
18S rRNA. The relative
level of target gene normalized to 18S rRNA was deter-
mined by calculating: 2–
Ct.
For the 2–
Ct calculation to be valid, preliminary vali-
dation experiments were performed to verify that the effi-
ciencies of target gene amplification and the efficiency of
18S rRNA amplification were approximately equal. To
achieve this, standard curves of template dilution and Ct
were obtained for each target gene and 18S rRNA to
confirm comparative rates of transcriptional efficiency for
each probe set.Fig 4, online only. Magnetic resonance imaging was used to compare the ex vivo aortic maximum diameter
measurement with the in vivo measurements at day 28. The two measurements were highly correlated with each other
